https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Patient and health care professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: a cross sectional survey. https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54477 Tue 27 Feb 2024 14:56:37 AEDT ]]> Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46000 C and ABCB1_c.3435C > T were included in the final model, whereby CLSN38 reduced from 76.8 to 55.1%. Conclusion: The identified UGT1A3_c.31 T > C and ABCB1_c.3435C > T variants, from wild type to homozygous, were included in the final model for SN38 clearance.]]> Tue 08 Nov 2022 16:32:22 AEDT ]]> Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54138 Tue 06 Feb 2024 11:56:59 AEDT ]]> A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48437 Thu 16 Mar 2023 14:25:14 AEDT ]]> Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51568 Mon 11 Sep 2023 14:22:09 AEST ]]>